Abstract
Background Bendamustine may be a potential treatment option for patients with myeloma, but little is known about the utility of bendamustine as a salvage treatment, especially in Asian patients. Methods We performed a multicenter retrospective study of patients with relapsed or refractory myeloma who received bendamustine and prednisone. Results The records of 65 heavily pre-treated patients, who had undergone bortezomib and lenalidomide treatment (median number of previous treatments: 5), were analyzed. The median time from diagnosis to bendamustine treatment was 3.8 years, and the median patient age was 63 years (range, 38-77 yr). The responses to the last treatment before bendamustine were refractory disease (N=52, 80%) or disease progression from partial response (N=13, 20%). Twenty-three patients responded to the treatment, with an overall response rate of 35% (23/65), and the median number of bendamustine treatment cycles was two (range, 1-5 cycles). The median overall survival after bendamustine treatment was 5.5 months and the overall survival rate in responders to bendamustine was significantly better than that in non-responders (P=0.036). Conclusion Bendamustine may be a potential salvage treatment to extend survival in a select group of heavily pre-treated patients with relapsed or refractory myeloma.
| Original language | English |
|---|---|
| Pages (from-to) | 193-199 |
| Number of pages | 7 |
| Journal | Blood Research |
| Volume | 51 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2016 Jan 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Hematology
Cite this
}
Bendamustine in heavily pre-treated multiple myeloma patients : Results of a retrospective analysis from the Korean Multiple Myeloma Working Party. / On behalf of the Korean Multiple Myeloma Working Party.
In: Blood Research, Vol. 51, No. 3, 01.01.2016, p. 193-199.Research output: Contribution to journal › Article
TY - JOUR
T1 - Bendamustine in heavily pre-treated multiple myeloma patients
T2 - Results of a retrospective analysis from the Korean Multiple Myeloma Working Party
AU - On behalf of the Korean Multiple Myeloma Working Party
AU - Kim, Seok Jin
AU - Bang, Soo Mee
AU - Choi, Yoon Seok
AU - Jo, Deog Yeon
AU - Kim, Jinseok
AU - Lee, Hyewon
AU - Eom, Hyeon Seok
AU - Yoon, Dok Hyun
AU - Suh, Cheolwon
AU - Lee, Je Jung
AU - Hong, Junshik
AU - Lee, Jae Hoon
AU - Koh, Youngil
AU - Kim, Kihyun
AU - Yoon, Sung Soo
AU - Min, Chang Ki
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Background Bendamustine may be a potential treatment option for patients with myeloma, but little is known about the utility of bendamustine as a salvage treatment, especially in Asian patients. Methods We performed a multicenter retrospective study of patients with relapsed or refractory myeloma who received bendamustine and prednisone. Results The records of 65 heavily pre-treated patients, who had undergone bortezomib and lenalidomide treatment (median number of previous treatments: 5), were analyzed. The median time from diagnosis to bendamustine treatment was 3.8 years, and the median patient age was 63 years (range, 38-77 yr). The responses to the last treatment before bendamustine were refractory disease (N=52, 80%) or disease progression from partial response (N=13, 20%). Twenty-three patients responded to the treatment, with an overall response rate of 35% (23/65), and the median number of bendamustine treatment cycles was two (range, 1-5 cycles). The median overall survival after bendamustine treatment was 5.5 months and the overall survival rate in responders to bendamustine was significantly better than that in non-responders (P=0.036). Conclusion Bendamustine may be a potential salvage treatment to extend survival in a select group of heavily pre-treated patients with relapsed or refractory myeloma.
AB - Background Bendamustine may be a potential treatment option for patients with myeloma, but little is known about the utility of bendamustine as a salvage treatment, especially in Asian patients. Methods We performed a multicenter retrospective study of patients with relapsed or refractory myeloma who received bendamustine and prednisone. Results The records of 65 heavily pre-treated patients, who had undergone bortezomib and lenalidomide treatment (median number of previous treatments: 5), were analyzed. The median time from diagnosis to bendamustine treatment was 3.8 years, and the median patient age was 63 years (range, 38-77 yr). The responses to the last treatment before bendamustine were refractory disease (N=52, 80%) or disease progression from partial response (N=13, 20%). Twenty-three patients responded to the treatment, with an overall response rate of 35% (23/65), and the median number of bendamustine treatment cycles was two (range, 1-5 cycles). The median overall survival after bendamustine treatment was 5.5 months and the overall survival rate in responders to bendamustine was significantly better than that in non-responders (P=0.036). Conclusion Bendamustine may be a potential salvage treatment to extend survival in a select group of heavily pre-treated patients with relapsed or refractory myeloma.
UR - http://www.scopus.com/inward/record.url?scp=84994853809&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84994853809&partnerID=8YFLogxK
U2 - 10.5045/br.2016.51.3.193
DO - 10.5045/br.2016.51.3.193
M3 - Article
AN - SCOPUS:84994853809
VL - 51
SP - 193
EP - 199
JO - Blood Research
JF - Blood Research
SN - 2287-979X
IS - 3
ER -